This morning, Array Biopharma will outline its plans to investors to get its first wholly-owned drug, a treatment for the blood cancer multiple myeloma, approved by the Food and Drug Administration.
A difficult 2021 for Array Technologies appears to have given way to a positive 2022 as the company recovers from damaging supply side issues. Image: Array US solar tracker supplier Array Technologies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback